Literature DB >> 19620942

DNA mismatch repair deficiency in endometrial carcinoma.

Yevgeniy Karamurzin1, Joanne K L Rutgers.   

Abstract

Microsatellite instability (MSI) is the hallmark of a molecular pathway to carcinogenesis due to sporadic or inherited abnormalities of DNA mismatch repair genes. Inherited mutations are seen in hereditary nonpolyposis colorectal cancer syndrome. Endometrial carcinoma shows as high an incidence of MSI as does colorectal carcinoma. This review provides a framework for the gynecologic pathologist to understand the complexities of MSI in endometrial carcinoma, by discussing the basic mechanisms of mismatch repair and carcinogenesis, testing, the morphologic features of MSI endometrial cancer and the contradictory data regarding prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19620942     DOI: 10.1097/PGP.0b013e31818d8fe6

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  24 in total

1.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Authors:  Lydia W T Cheung; Bryan T Hennessy; Jie Li; Shuangxing Yu; Andrea P Myers; Bojana Djordjevic; Yiling Lu; Katherine Stemke-Hale; Mary D Dyer; Fan Zhang; Zhenlin Ju; Lewis C Cantley; Steven E Scherer; Han Liang; Karen H Lu; Russell R Broaddus; Gordon B Mills
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

2.  Implications for damage recognition during Dpo4-mediated mutagenic bypass of m1G and m3C lesions.

Authors:  Olga Rechkoblit; James C Delaney; John M Essigmann; Dinshaw J Patel
Journal:  Structure       Date:  2011-06-08       Impact factor: 5.006

3.  The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.

Authors:  B Smith; R Neff; D E Cohn; F J Backes; A A Suarez; D G Mutch; C M Rush; C J Walker; P J Goodfellow
Journal:  Gynecol Oncol       Date:  2016-08-15       Impact factor: 5.482

4.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

5.  Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist.

Authors:  Molly S Daniels; Diana L Urbauer; Azadeh Zangeneh; Brittany A L Batte; Katherine M Dempsey; Karen H Lu
Journal:  Gynecol Oncol       Date:  2013-10-17       Impact factor: 5.482

6.  A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome.

Authors:  Ping Gong; Sarah Charles; Norman Rosenblum; Zoe Wang; Agnieszka K Witkiewicz
Journal:  Gynecol Oncol Case Rep       Date:  2012-03-15

7.  Comprehensive genome- and transcriptome-wide analyses of mutations associated with microsatellite instability in Korean gastric cancers.

Authors:  Kwiyeom Yoon; Sunghoon Lee; Tae-Su Han; So Yeon Moon; Sun Mi Yun; Seong-Ho Kong; Sungwoong Jho; Jinny Choe; Jieun Yu; Hyuk-Joon Lee; Ji Hyun Park; Hak-Min Kim; So Yeun Lee; Jongsun Park; Woo-Ho Kim; Jong Bhak; Han-Kwang Yang; Seong-Jin Kim
Journal:  Genome Res       Date:  2013-06-04       Impact factor: 9.043

8.  Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain.

Authors:  Shuk On Annie Leung; Olivia Foley; David Chapel; Annacarolina Da Silva; Marisa Nucci; Michael G Muto; Susana Campos
Journal:  Oncologist       Date:  2021-08-26

9.  The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.

Authors:  Ekta Jain; Sarita Prasad; Aparna Dhar; Lata Kini; Shivani Sharma; Aditi Dewan
Journal:  Pathologica       Date:  2021-04

10.  Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.

Authors:  Mayumi Kobayashi Kato; Hiroshi Yoshida; Yasuhito Tanase; Masaya Uno; Mitsuya Ishikawa; Tomoyasu Kato
Journal:  Pathol Oncol Res       Date:  2021-03-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.